Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis

References

• Boeree MJ, Heinrich N, Aarnoutse R, et al.; PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49. PMID: 28100438; PMCID: PMC5159618. doi:10.1016/S1473-3099(16)30274-2
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/ RR-TB); 2018.
   Google Scholar
• Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47:653–657. doi:10.1128/AAC.47.2.653-657.2003
   PubMed Web of Science ®Google Scholar
• Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother. 2002;46:1875–1879. doi:10.1128/AAC.46.6.1875-1879.2002
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al.; Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-1
   PubMed Web of Science ®Google Scholar
• Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204:1951–1959. doi:10.1093/infdis/jir658
   PubMed Web of Science ®Google Scholar
• Van’t Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, et al. Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients. Antimicrob Agents Chemother. 2017;61:e00343–17. doi:10.1128/AAC.00343-17
   PubMed Web of Science ®Google Scholar
• Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J. 2011;38:888–894. doi:10.1183/09031936.00176610
   PubMed Web of Science ®Google Scholar
• Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928–933. doi:10.1038/35057149
   PubMed Web of Science ®Google Scholar
• Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics. 2016;14:298–313. doi:10.1016/j.gpb.2016.03.008
   PubMed Web of Science ®Google Scholar
• Inge WS, Ulrich K. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet. 1996;31:47–64. doi:10.2165/00003088-199631010-00004
   Web of Science ®Google Scholar
• Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC. The role of fluoroquinolones in the treatment of tuberculosis in 2019. Drugs. 2019;79(2):161–171. PMID: 30617959; PMCID: PMC6373389. doi:10.1007/s40265-018-1043-y
   PubMed Web of Science ®Google Scholar
• Pranger AD, Alffenaar JW, Aarnoutse RE. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamics approach. Curr Pharm Des. 2011;17(27):2900–2930. doi:10.2174/138161211797470200
   Web of Science ®Google Scholar
• Firsov AA, Lubenko IY, Portnoy YA, Zinner SH, Vostrov SN. Relationships of the area under the curve/ MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother. 2001;45:927–931. doi:10.1128/AAC.45.3.927-931.2001
   PubMed Web of Science ®Google Scholar
• Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–12. doi:10.1086/516284
   PubMed Web of Science ®Google Scholar
• Craig W. Does dose matter? Clin Infect Dis. 2001;33(Suppl. 3):S233–S237. doi:10.1086/321854
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190:1642–1651. doi:10.1086/424849
   PubMed Web of Science ®Google Scholar
• Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51:576–582. doi:10.1128/AAC.00414-06
   PubMed Web of Science ®Google Scholar
• Deshpande D, Pasipanodya JG, Mpagama SG, et al. Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis. Levofloxacin for drug-resistant tuberculosis. Clin Infect Dis. 2018;67(Suppl 3):S293–S302. doi:10.1093/cid/ciy611
   Web of Science ®Google Scholar
• World Health Organization. WHO Global Lists of High Burden Countries for TB, Multidrug/Rifampicin-Resistant TB (MDR/RR-TB) and TB/HIV, 2021–2025. Geneva: World Health Organization; 2021. Licence: CC BY-NCSA 3.0 IGO.
   Google Scholar
• Adamu AY. Diversity in Ethiopia. Int J Commun Div. 2013;12(3):17–27. doi:10.18848/2327-0004/CGP/v12i03/39924
   Google Scholar
• FMOH/CDC. 16th national annual review meeting group discussion. Why TB? Evaluating the national TB control program: challenges and ways forward; 2014.
   Google Scholar
• Sidamo T, Shibeshi W, Yimer G, Aklillu E, Engidawork E. Explorative analysis of treatment outcomes of levofloxacin- and moxifloxacin-based regimens and outcome predictors in Ethiopian MDR-TB patients: a prospective observational cohort study. Infect Drug Resist. 2021;14:5473–5489. doi:10.2147/IDR.S342964
   Web of Science ®Google Scholar
• World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Federal Democratic Republic of Ethiopia. National Guidelines for TB, DR-TB and Leprosy, Federal Ministry of Health. 6th ed. Addis Ababa: Federal Democratic Republic of Ethiopia; 2017.
   Google Scholar
• World Health Organization. Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update. Geneva: World Health Organization; 2017.
   Google Scholar
• Kim HJ, Seo KA, Kim HM, et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal. 2015;102:9–16. doi:10.1016/j.jpba.2014.08.026
   PubMed Web of Science ®Google Scholar
• Schon T, Werngren J, Machado D, et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates the EUCAST broth microdilution reference method for MIC determination. Clinical Microbiol Infect. 2020;26:1488–1492. doi:10.1016/j.cmi.2020.07.036
   Web of Science ®Google Scholar
• Rockwood N, Bruyn ED, Morris T, Wilkinson RJ. Assessment of treatment response in tuberculosis. Expert Rev Respir Med. 2016;10(6):643–654. doi:10.1586/17476348.2016.1166960
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Hadad DJ, Molino LPD, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(3):852–857. doi:10.1128/AAC.01036-07
   Web of Science ®Google Scholar
• Alsultan A, An G, Peloquin CA. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. Antimicrob Agents Chemother. 2015;59(7):3800–3807. PMID: 25870068; PMCID: PMC4468713. doi:10.1128/AAC.00341-15
   PubMed Web of Science ®Google Scholar
• Yun H-Y, Chang V, Radtke KK, et al. Model-based efficacy and toxicity comparisons of moxifloxacin for multidrug-resistant tuberculosis. Open Forum Infect Dis. 2022;9(3):ofab660. doi:10.1093/ofid/ofab660
   Web of Science ®Google Scholar
• Zvada SP, Denti P, Sirgel FA, et al. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrob Agents Chemother. 2014;58(1):503. doi:10.1128/AAC.01478-13
   PubMed Web of Science ®Google Scholar
• Xu XS, Yuan M, Karlsson MO, Dunne A, Nandy P, Vermeulen A. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J. 2012;14:4. doi:10.1208/s12248-012-9407-9
   Web of Science ®Google Scholar
• van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, et al. Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients. Antimicrob Agents Chemother. 2019;63:e00384–19. doi:10.1128/AAC.00384-19
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines Used in the Treatment of Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• Angeby KA, Jureen P, Giske CG, et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother. 2010;65:946–952. doi:10.1093/jac/dkq091
   PubMed Web of Science ®Google Scholar
• Tornheim JA, Udwadia ZF, Arora PR, et al. Increased moxifloxacin dosing among patients with multidrug-resistant tuberculosis with low-level resistance to moxifloxacin did not improve treatment outcomes in a tertiary care center in Mumbai. India Open Forum Infect Dis. 2021;9(2):ofab615. PMID: 35097152; PMCID: PMC8794589. doi:10.1093/ofid/ofab615
   Web of Science ®Google Scholar
• Rajman I, Knapp L, Hanna I. Genetic diversity in drug transporters: impact in African populations. Clin Transl Sci. 2020;13:848–860. doi:10.1111/cts.12769
   PubMed Web of Science ®Google Scholar
• Naidoo R, Ramsuran V, Chirehwa M, et al. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics. 2018;19(1). doi:10.2217/pgs-2017-0144
   Web of Science ®Google Scholar
• Mugusi S, Habtewold A, Ngaimisi E, et al. Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort study in two Sub-Sahara African populations. Front Pharmacol. 2020;11:26. doi:10.3389/fphar.2020.00026
   PubMed Web of Science ®Google Scholar
• Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol. 2009;49:674–683. doi:10.1177/0091270008330984
   PubMed Web of Science ®Google Scholar
• Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother. 1999;43(SupplB):69–76. doi:10.1093/jac/43.suppl_2.69
   Web of Science ®Google Scholar
• Rumende CM. Risk factors for multidrug-resistant tuberculosis. Acta Media Indonesia. 2018;50:1.
   PubMed Web of Science ®Google Scholar
• Enroth S, Hallmans G, Grankvist K, Gyllensten U. Effects of long-term storage time and original sampling month on biobank plasma protein concentrations. EBioMedicine. 2016;12:309–314. PMID: 27596149; PMCID: PMC5078583. doi:10.1016/j.ebiom.2016.08.038
   PubMed Web of Science ®Google Scholar
• Mitchella BL, Yasuie Y, Li CI, Fitzpatrick AL, Lampe PD. Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry based biomarker discovery projects. Cancer Inform. 2005;1:98–104.
   Google Scholar
• Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol. 2014;10(6):813–823. doi:10.1517/17425255.2014.895813
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15:353. doi:10.1186/1745-6215-15-353
   PubMed Web of Science ®Google Scholar
• Kuhlin J, Sturkenboom MGG, Ghimire S, et al. Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs. Clin Mass Spectr. 2019;14:34–45. doi:10.1016/j.clinms.2018.10.002
   Google Scholar
• Davies Forsman L, Bruchfeld J, Alffenaar J-WC. Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis. Eur Respir J. 2017;49:1700173. doi:10.1183/13993003.00173-2017
   Web of Science ®Google Scholar
• Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1. doi:10.3904/kjim.2009.24.1.1
   PubMedGoogle Scholar
• Nielsen EI, Friberg LE, Friberg LE. Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother. 2011;55:4619–4630. doi:10.1128/AAC.00182-11
   PubMed Web of Science ®Google Scholar
• Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J. 2013;42(6):1449–1453. doi:10.1183/09031936.00073213
   Web of Science ®Google Scholar
• Ghimire S, Bolhuis MS, Sturkenboom MG, et al. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. Eur Respir J. 2016;47:1867–1869. doi:10.1183/13993003.00040-2016
   PubMed Web of Science ®Google Scholar
• Mohamed S, Mvungi HC, Sariko M, et al. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania - PubMed (nih.gov). J Antimicrob Chemother. 2021;76(6):1547–1552. doi:10.1093/jac/dkab057
   Web of Science ®Google Scholar
• van den Elsen SHJ, Oostenbrink LM, Heysell SK, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring - PubMed (nih.gov). Drug Monit. 2018;40(1):17–37. PMID: 29120971; PMCID: PMC6345279. doi:10.1097/FTD.0000000000000462
   Web of Science ®Google Scholar
• Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume - PubMed (nih.gov). J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(15–16):1063–1070. PMID: 21459055. doi:10.1016/j.jchromb.2011.03.017
   PubMed Web of Science ®Google Scholar